

NOT FOR DISTRIBUTION OR PUBLICATION, TOTALLY OR PARTIALLY, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR IN ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE UNLAWFUL.



Hecho relevante

Relaciones con Inversores
Inv. Institucionales y analistas
Tel. +34 91 595 10 00
Oficina del Accionista
Tel. +34 902 30 10 15
relaciones.inversores@abertis.com

COMISION NACIONAL DEL MERCADO DE VALORES (CNMV)

ABERTIS INFRAESTRUCTURAS, S.A. ("**Abertis**"), in compliance with article 82 of Law 24/1988 of 28 July on the Securities Market, hereby notifies the following

RELEVANT FACT

Today, Morgan Stanley & Co. International plc, Goldman Sachs International and CaixaBank, S.A. as Joint Global Coordinators of the offering of Cellnex Telecom, S.A. shares ("**Cellnex**" and the "**Offering**", respectively), acting on behalf of itself and the Managers, have exercised the over-allotment option (*green shoe*) granted by Abertis to purchase 13,900,994 additional Cellnex shares. In compliance with the underwriting agreement entered into on 5 May 2015, the price agreed for the exercise of the over-allotment option corresponds to the price of the Offering, that is, EUR 14 per share.

With the exercise of this over-allotment option the stabilization period is concluded prior to the period referred to in section 6.5 of the share securities note in the Prospectus, which was initially expected to end on the 30th natural day after Cellnex's shares admission to trading. In this regard, in compliance with article 9.3 of the Commission Regulation (CE) 2273/2003 of 22 December 2003 on exceptions for buy-back programmes and stabilisation of financial instruments, and in accordance with the information received from Morgan Stanley & Co. International plc, as Stabilization Agent of the Offering, it is hereby notified that no stabilisation activity has been undertaken with regard to Cellnex's shares after admission to trading on the Spanish Stock Exchanges.

Barcelona, 18 May 2015

abertis.com / relaciones.inversores@abertis.com

Notice: This document is a translation of a duly approved Spanish language document, and is provided for information purposes only. In the event of any discrepancy between the text of this translation and the text of the original Spanish language document which this translation is intended to reflect, the text of the original Spanish language document shall prevail.

NOT FOR DISTRIBUTION OR PUBLICATION, TOTALLY OR PARTIALLY, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR IN ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE UNLAWFUL.

IMPORTANT NOTICE

This document does not constitute an offer for the sale of securities, nor a request or offer to purchase or subscribe securities in the Unites States of America, Australia, Canada, Japan or any other jurisdiction in which this offer, request or sale is unlawful.

The securities will not be offers or sold in the Unites States of America unless they are registered under the applicable legislation or are exempt from registration. There is no intention to register a portion of the Offering in the Unites States of America or to make a public offer of securities in the Unites States of America.

Any public offer of securities to be made by Cellnex in the Unites States of America, must be by a prospectus that contains detailed information on Cellnex and its directors, and regarding its financial statements. Copies of this document may not be published, distributed or sent to the Unites States of America, Canada, Australia, Japan or any other jurisdiction in which such information is restricted by law.

This announcement is an advertisement and not a prospectus.

The relevant prospectus on the initial public offer and admission to trading of shares of Cellnex on the Spanish Stock Exchanges has been duly approved by the Comisión Nacional del Mercado de Valores ("CNMV") and was registered in its official registry on 23 April 2015, as amended to increase the number of shares offered by the supplement registered by the CNMV on 4 May 2015. The prospectus and the supplement are available to the investors on the Cellnex and the CNMV web sites, and on Cellnex's corporate register, each of the Spanish Stock Exchanges and the participant entities of the Offering and Agent Entity.

abertis.com / relaciones.inversores@abertis.com

Notice: This document is a translation of a duly approved Spanish language document, and is provided for information purposes only. In the event of any discrepancy between the text of this translation and the text of the original Spanish language document which this translation is intended to reflect, the text of the original Spanish language document shall prevail.